

GBS History, Meningococcal Vaccination

BY SHARON WORCESTER

FROM A MEETING OF THE CDC'S ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES

ATLANTA — The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices voted at its June meeting to remove language from its meningococcal vaccine statement warning that a history of Guillain-Barré syndrome should be considered a "precaution" to administering meningococcal conjugate vaccines.

The action followed the presentation of final results of a study conducted at Harvard Medical School/Harvard Pilgrim Healthcare involving nearly 12.6 million individuals aged 11-21 years.

No cases of Guillain-Barré syndrome (GBS) occurred within 6 weeks of vaccination in any of the 1.4 million participants who received quadrivalent meningococcal conjugate vaccine (MCV4, Menactra) doses, Priscilla Vejentgas, Ph.D., of Harvard Medical School and the Harvard Pilgrim Health Care Institute, Boston, reported.

"This study provided no evidence of increased risk of GBS associated with MCV4," she said.

Concern over a link between meningococcal conjugate vaccines and GBS arose in 2006. In October of that year, the CDC published findings from the Vaccine Adverse Event Reporting System (VAERS) indicating that the observed rate of GBS within 6 weeks of vaccination appeared to be elevated among adolescents aged 15-19 years.

The passive VAERS reporting system thus generated a "signal" of a possible problem, which triggered a CDC investigation using the Vaccine Safety Datalink.

That investigation also found no link between MCV4 and increased risk of GBS.

On the recommendation of the ACIP meningococcal working group, the committee voted to remove all precautionary language from the meningococcal statement, and background language will include relevant VAERS information and data from the studies showing no increased risk of GBS after meningococcal conjugate vaccine administration in the general population.

Additionally, the matter will be sent to the ACIP General Recommendations Working Group to address the risks and benefits of receiving any vaccine in a person with a history of postvaccine GBS. ■

Disclosures: Dr. Vejentgas said both Harvard Pilgrim Care and Outcome Sciences have accepted research funding from vaccine manufacturers, and that she is an employee of both. The study was funded by Sanofi Pasteur through a contract with Harvard Pilgrim.

Seasonal Flu Vaccine Recs for Kids Updated

BY SHARON WORCESTER

FROM A MEETING OF THE CDC'S ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES

ATLANTA — Children ages 6 months through 8 years who did not receive at least one dose of the 2009 influenza A(H1N1) monovalent vaccine during the 2009-2010 influenza season should receive two doses of a 2010-2011 seasonal influenza vaccine, which will include H1N1 coverage, according to a


new recommendation from the Centers for Disease Control and Prevention.

Prior recommendations stated that children in this age group who received two doses in the first influenza season in which they are vaccinated require only one dose the following season.

The CDC's Advisory Committee on Immunization Practices (ACIP) voted June 24 to make this change to its existing seasonal influenza vaccination recommendations.

The recommendations continue to state that children ages 6 months through 8 years who are receiving a seasonal vaccine for the first time should receive two doses, and that those who received only one dose of a seasonal vaccine in the first influenza season in which they were vaccinated should receive two doses in the following season.

If children in this age group received at least one dose of 2009 H1N1



DEXILANT WORKS A SECOND SHIFT TO HELP SHUT DOWN ACID PUMPS

flu vaccine last year, they need only one dose of the seasonal vaccine in 2010-2011, provided they received two doses of seasonal flu vaccine in their first year of receiving seasonal vaccines.

The additional recommendation was made in light of immunogenicity and vaccine effectiveness data suggesting that children under age 9 years who receive only one dose of a 2009 H1N1 flu vaccine instead of the recommended two doses have

reduced rates of seroconversion.

Children in that age group also have lower rates of immunity resulting from natural influenza infection.


The ACIP Influenza Vaccine Working Group, which proposed the change, reported that protective titers of hemagglutinin inhibition following a single dose of a 2009 H1N1 monovalent vaccine during the 2009 pandemic occurred in as few as 19% of children aged 6 months to 3 years, and as few as 44% of

those aged 3-9 years.

Protective titers were present in at least 90% of older children and adults up to age 65 years, and in 81% of those age 65 and older.

After two doses, 73%-100% of infants and young children developed protective titers. ■

Disclosures: Dr. Shay said he had no conflicts of interest, and Dr. Lieu said she had none other than that the studies were funded by the CDC and FDA.




©GINA SANDERS/FOTOLIA.COM

If a child aged 6 months to 8 years received at least one dose of 2009 H1N1 flu vaccine last year, he needs only one dose of the seasonal vaccine in 2010-2011, provided he received two doses of seasonal flu vaccine in his first year of receiving seasonal flu vaccine.



DEXILANT is the first and only PPI with a Dual Delayed Release™ (DDR) formulation, which provides a second release of drug



- DEXILANT 30 mg provided full 24-hour heartburn relief in a majority of symptomatic non-erosive gastroesophageal reflux disease patients at week 4¹

Conclusions of comparative efficacy cannot be drawn from this information.

Indications

DEXILANT is indicated for healing all grades of erosive esophagitis (EE) for up to 8 weeks, maintaining healing of EE for up to 6 months, and treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for 4 weeks.

Important Safety Information

DEXILANT is contraindicated in patients with known hypersensitivity to any component of the formulation. Hypersensitivity and anaphylaxis have been reported with DEXILANT use. Symptomatic response with DEXILANT does not preclude the presence of gastric malignancy. Most commonly reported treatment-emergent adverse reactions: diarrhea (4.8%), abdominal pain (4.0%), nausea (2.9%), upper respiratory tract infection (1.9%), vomiting (1.6%), and flatulence (1.6%). Do not co-administer atazanavir with DEXILANT because atazanavir systemic concentrations may be substantially decreased. DEXILANT may interfere with absorption of drugs for which gastric pH is important for bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole). Patients taking concomitant warfarin may require monitoring for increases in international normalized ratio (INR) and prothrombin time. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Concomitant tacrolimus use may increase tacrolimus whole blood concentrations.

Please see adjacent brief summary of prescribing information for DEXILANT.

**FORMERLY
KAPIDEX™**
(dexlansoprazole)

DEXILANT™
dexlansoprazole
30 MG | 60 MG DELAYED RELEASE CAPSULES

Two releases. One pill.